Cyclacel Pharmaceuticals announces multiple presentations at American Association of Cancer Research Annual Meeting

BERKELEY HEIGHTS, NJ – April 7, 2008 – Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) announced today the presentation of eight posters highlighting preclinical data of Cyclacel’s cell cycle inhibitors, sapacitabine, seliciclib and CYC116, at the upcoming American Association of Cancer Research (AACR) Annual Meeting. The meeting is being held in the San Diego Convention Center in San Diego, CA from April 12 - 16, 2008.

Details of the poster presentations referring to specific Cyclacel programs are as follows:

Sapacitabine

“Impact of DNA repair proteins on cell survival in response to damage induced by the DNA self-strand-breaking nucleoside analogue CNDAC”*

Date/Time: Sunday, Apr 13, 2008, 8:00 AM - 12:00 PM

Abstract Number: 638

Seliciclib

“Optimal cancer chronotherapeutics schedules of seliciclib revealed by a systems biology approach”*

Date/Time: Sunday, Apr 13, 2008, 1:00 PM - 5:00 PM

Abstract Number: 801

“Potential therapeutic role of seliciclib in combination with ionizing radiation for human nasopharyngeal carcinoma”

Date/Time: Wednesday, April 16, 2008, 8:00 AM – 12:00 PM PST

Abstract Number: 5511

CYC116

“The basis of cell sensitivity to Aurora A/B inhibitors”

Date/Time: Sunday, April 13, 2008, 8:00 AM – 12:00 PM PST

Abstract Number: 651

“Systems biology analysis of a novel Aurora kinase inhibitor: CYC116”

Date/Time: Monday, April 14, 2008, 8:00 AM – 12:00 PM PST

Abstract Number: 1645

“Combination studies with the oral Aurora kinase inhibitor CYC116 and chemotherapeutic agents”

Date/Time: Tuesday, April 15, 2008, 8:00 AM – 12:00 PM PST

Abstract Number: 4015

“In vivo mode of action of CYC116, a novel small molecule inhibitor of Aurora kinases and VEGFR2”

Date/Time: Wednesday, April 16, 2008, 8:00 AM – 12:00 PM PST

Abstract Number: 5645

“Anti-tumor activity of CYC116, a novel small molecule inhibitor of Aurora kinases and VEGFR2”

Date/Time: Wednesday, April 16, 2008, 8:00 AM – 12:00 PM PST

Abstract Number: 5644

The abstracts are currently available online at www.aacr.org .

*Note: asterisks denote research conducted by independent investigators.

About Cyclacel Pharmaceuticals, Inc – www.cyclacel.com 

Cyclacel is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three Cyclacel drugs are in clinical development. Sapacitabine (CYC682), an orally-available cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly and cutaneous T-cell lymphoma (CTCL). Seliciclib (CYC202), an orally-available CDK (cyclin dependent kinase) inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer. CYC116, an orally-available, Aurora kinase and VEGFR2 inhibitor, is in Phase 1 in patients with solid tumors. Several additional programs are at an earlier stage. Cyclacel’s ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair™ Cream for radiation dermatitis, Numoisyn™ Liquid and Numoisyn™ Lozenges for xerostomia. Cyclacel’s strategy is to build a diversified biopharmaceutical business focused in oncology, hematology and other therapeutic areas based on a portfolio of commercial products and a development pipeline of novel drug candidates.

Note: The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc. Numoisyn™ and Xclair™ are trademarks of Sinclair Pharma plc.

Risk Factors

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety, and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risk that Cyclacel will not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed under "Risk Factors" in the Annual Report on Form 10-K for the year ended December 31, 2007, as supplemented by the interim quarterly reports, filed with the SEC.

For more information, please contact

College Hill
Life Sciences
Sue Charles / Justine Lamond / Claire Mosley / John McIntyre
Ph: +44 (0)20 7866 7857
Cyclacel@collegehill.com